Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan

Area of Science:

• Pharmacology and Drug Development
• Oncology and Cancer Therapeutics
• Global Health and Regulatory Science

Background:

• Cancer poses a significant global health burden with high mortality and unmet medical needs.
• Innovative anticancer drugs, particularly first-in-class (FIC) agents, are in high demand but face unequal availability worldwide.
• Understanding regional drug development and approval disparities is essential to address global inequities in cancer care.

Purpose of the Study:

• To investigate the development and approval landscape of first-in-class (FIC) anticancer drugs in the United States (US), European Union (EU), and Japan over the past two decades.
• To quantify and compare drug approval timelines and identify submission and approval lags between these major economic regions.
• To provide fundamental insights into how global demands for innovative anticancer therapies are met and to highlight areas for improvement in international drug accessibility.

Main Methods:

• Identification of first-in-class (FIC) anticancer drugs utilizing pharmacological classification systems relevant to the Japanese drug pricing structure.
• Analysis of drug approval data from the US, EU, and Japan over the last 20 years.
• Statistical comparison of median approval times and calculation of submission and approval lags between the specified regions.

Main Results:

• The United States (US) served as the primary region for the initial approval of most identified FIC anticancer drugs.
• Japan exhibited a significantly longer median approval time for new pharmacological class anticancer drugs (5072 days) compared to the US (4253 days) (p=0.043), but not significantly different from the EU (4655 days).
• Substantial submission and approval lags were observed: over 2.1 years between the US and Japan, and over 1.2 years between the EU and Japan, while the US-EU lag was less than 0.8 years, indicating slower development rates in Japan.

Conclusions:

• Significant drug lag exists for first-in-class (FIC) anticancer drugs, particularly impacting Japan's access compared to the US and EU.
• The development and approval rate of FIC anticancer drugs in Japan is demonstrably slower than in other major developed regions.
• An improved international cooperative framework is necessary to reduce regional drug lags and enhance global patient access to life-saving cancer therapies.